Xuebin Qin, Md, Phd
Xuebin Qin, Md, Phd
Associate Professor of Neuroscience

Temple University


Wannan Medical College, China MD


Tongji Medical University, China MS


Human Genetics
Peking Union Medical College & Chinese Academy of Medical Science, China PhD


Molecular Biology




Research Interest

My research focuses on defining the role of the complement in the pathogenesis of human diseases such as cancer, virus infection, and cardiovascular diseases.

  1. Development of therapeutic anti-hCD59 inhibitor for HIV and Ab-based cancer therapy
  2. Role of complement system in the pathogenesis of atherosclerosis and aneurysm
  3. Development of a universal cell ablation model and studies of the pathogenesis of hemolysis-associated pulmonary hypertension

Professional Activities:

1986-1988 Resident Doctor of Pediatric Department, Tongling Hospital, Anhui, China
1991-1993 Director of Medical Genetics Laboratory, Tongling Hospital, Anhui, China
1996-1998 Postdoctoral Fellow, Dept. of Physiology, Tufts University School of Medicine, Boston, MA
1998-2001 Research Associate, Harvard Medical School, Boston, MA
2002-2006 Instructor in Medicine, Harvard Medical School, Boston, MA
2006-2013 Assistant Professor in Medicine, Harvard Medical School, Boston, MA
2013- Present Associate Professor of Neuroscience, Temple University School of Medicine


Honors and Awards





  1. Shao Y, Chernaya V, Johnson C, Yang WY, Cueto R, Sha X, Zhang Y, Qin X, Sun J, Choi ET, Wang H, Yang XF. Metabolic Diseases Downregulate the Majority of Histone Modification Enzymes, Making a Few Upregulated Enzymes Novel Therapeutic Targets-"Sand Out and Gold Stays". J Cardiovasc Transl Res. 2016 Jan 8. [Epub ahead of print]
  2. Lopez-Pastrana J, Ferrer L, Li YF, Xiong X, Xi H, Cueto R, Nelson JZ, Sha X, Li X, Cannella AL, Imoukhuede PI, Qin X, Choi E, Wang H, Yang XF. Inhibition of caspase-1 activation in endothelial cells improves angiogenesis -A novel therapeutic potential for ischemia. J Biol Chem. 2015 Jun 2. pii: jbc.M115.641191. [Epub ahead of print]
  3. Liu F, Wu L, Wu G, Wang C, Zhang L, Tomlison S*, Qin X*. Targeted mouse complement inhibitor CR2-Crry protects against the development of atherosclerosis in mice. Atherosclerosis. 2014 Mar 15;234(1):237-243 (Epub ahead of print) (* are indicative of senior authors for the paper) (IF: 3.971) (cited by 6).
  4. Cai B, Xie S, Liu F, Simone LC, Caplan S*, Qin X*, Naslavsky N*. Rapid Degradation of the Complement Regulator, CD59, by a Novel Inhibitor. J Biol Chem. 2014 Apr 25;289(17):12109-25. (* are indicative of senior authors for the paper) (IF: 5.117) (cited by 1)
  5. Liu F, Dai S, Gordon J, Qin X. Complement and HIV-I infection/HIV-associated neurocognitive disorders. J Neurovirol. 2014 Apr;20(2):184-98 (IF: 2.850)
  6. Niu N, Qin X. New insights into IL-7 signaling pathways during early and late T cell development. Cell Mol Immunol. 2013 Apr 15. doi: 10.1038/cmi.2013.11. (IF:2.992) (cited by 1).
  7. Liang S, Qin X. Critical role of type I interferon-induced macrophage necroptosis during infection with Salmonella enterica serovar Typhimurium. Cell Mol Immunol. 2013 Mar;10(2):99-100. (IF:2.992) (cited by 2)
  8. Wu L, Su S, Liu F, Xu T, Wang X, Huang Y, Sun X, Ge X, Chen T, Liu H, Wang C, Chorev M, Xu T, Qin X. Removal of the tag from His-tagged ILYd4, a human CD59 inhibitor, significantly improves its physical properties and its activity. Curr Pharm Des. 2012;18(27):4187-96. (IF: 4.77) (cited by 4)
  9. Wang Y, Chen W, Yang C, Wu W, Wu S, Qin X, Li X. Long non-coding RNA UCA1a(CUDR) promotes proliferation and tumorigenesis of bladder cancer. Int J Oncol. 2012 Jul;41(1):276-84. (IF: 2.399) (cited by 46)
  10. Soltys J, Halperin JA, Qin X. DAF/CD55 and Protectin/CD59 modulate adaptive immunity and disease outcome in experimental autoimmune myasthenia gravis. J Neuroimmunol. 2012 Mar;244(1-2):63-92. (IF: 3.2) (cited by 7)
  11. Amet T, Ghabril M, Chalasani N, Byrd D, Hu N, Grantham A, Liu Z, Qin X, He J. and Yu Q. CD59 incorporation protects hepatitis C virus against complement-mediated destruction. Hepatology. 2012 Feb;55(2):354-63. (IF:11.66) (cited by 27)
  12. Zhang J, Hu W, Xing W, You T, Xu, J, Qin, X, Peng Z. The protective role of CD59 and pathogenic role of complement in hepatic ischemia and reperfusion injury. Am J Pathol. 2011 Dec;179(6):2876-84. (IF:5.571) (cited by 13)
  13. Ge X, Wu L, Hu W, Fernandes S, Wang C, Li X, Brown JR, Qin X. rILYd4, a Human CD59 Inhibitor Enhances Complement Dependent Cytotoxicity of Ofatumumab against Rituximab-resistant B-cell Lymphoma Cells and Chronic Lymphocytic Leukemia. Clin Cancer Res. 2011 Nov 1;17(21):6702-11. (IF:8.742) (cited by 27)
  14. Sun H, Li M, Lu J, Yan D, Zhou C, Fan J, Qin X, Tang H, Peng Z. Overexpression of Forkhead box M1 protein associates with aggressive tumor features and poor prognosis of hepatocellular carcinoma. Oncol Rep. 2011;25(6):1533-9. (IF:1.835) (cited by 31)
  15. Sun H, Teng M, Liu J, Jin D, Wu J, Yan D, Fan J, Qin X, Tang H, Peng Z. FOXM1 expression predicts the prognosis in hepatocellular carcinoma patients after orthotopic liver transplantation combined with the Milan criteria. Cancer Lett. 2011; 306(2):214-22.  (IF:4.238) (cited by 27)
  16. Hu X, Ge X, You X, Xu T, Zhang J, Wu G, Peng Z, Chorev M, Aktas H, Halperin JA, Brown J, Qin X. Human CD59 inhibitor sensitizes rituximab resistant lymphoma cells to complement-mediated cytolysis.  Cancer Res. 2011; 71(6):2298-307. (IF: 9.856) (cited by 33)
  17. You T, Hu W, Ge X, Shen J, Qin X. Application of a novel inhibitor of human CD59 for the enhancement of complement-dependent cytolysis on cancer cells. Cell Mol Immunol. 2011; 8(2): 157-63. (IF: 2.992) (cited by 19)
  18. Hu W, Jin R, Zhang J, You T, Peng Z, Bronson RT, Halperin JA, Loscalzo J,  Qin X. The Critical Roles of Platelet Activation and Reduced NO Bioavailability in Fatal Pulmonary Arterial Hypertension in a Murine Hemolysis Model. Blood, 2010; 116(9):1613-22. (IF:9.898) (cited by 39)
  19. Gurdrun Z, Ming J, Jane CJ, Sema S, Chen T, Qin X, Aktas H. ELAV like HuR-dependent mRNA stability regulates post-transcriptional expression of cyclin dependent kinase inhibitor p27KIP1. Journal of Biological Chemistry. 2010; 285(20):15408-19. (IF:5.328) (cited by 14).
  20. Yu Q, Yu R, Qin X. The good and evil of complement activation in HIV-1 infection. Cell Mol Immunol. 2010; 7(5):334-40. (IF:2.992) (cited by 16)
  21. Wu G, Chen T, Shahsafaei A, Hu W, Bronson RT, Shi GP, Halperin JA, Aktas H, Qin X. Complement regulator CD59 protects against angiotensin II-induced abdominal aortic aneurysms in mice.  Circulation. 2010;121:1338-1346. (IF: 14.816) (cited by 26)
  22. Hu W, Yu Q, Hu N, Byrd D, Amet T, Shikuma C, Shiramizu B, Halperin JA, Qin X. A High-Affinity Inhibitor of Human CD59 Enhances Complement-Mediated Virolysis of HIV-1: Implications for Treatment of HIV-1/AIDS.J Immunol. 2010;184(1):359-68. (IF:5.788) (cited by 25)
  23. Tang H, Lu D, Pan R, Qin X, Xiong H, Dong J. Curcumin improves spatial memory impairment induced by human immunodeficiency virus type 1 glycoprotein 120 V3 loop peptide in rats. Life Sciences. 2009; 85(1-2), 1-10. (IF:2.732) (cited by 35)
  24. Wu G, Hu W, Shahsafaei A, Song W, Dobarro M, Sukhova GK, Bronson RR, Shi GP, Rother RP, Halperin JA, Qin X. Complement Regulator CD59 Protects Against Atherosclerosis by Restricting the Formation of Complement Membrane Attack Complex. Circulation Research. 2009; 104(4):550-558. (IF:11.498) (cited by 65)
  25. Pan H, Shen Z, Mukhopadhyay P, Wang H, Pacher P, Qin X, Gao B. Anaphylatoxin C5a Contributes to the Pathogenesis of Cisplatin-induced Nephrotoxicity. Am J Physiol Renal Physiol. 2009;296(3):F496-504. (IF:4.42) (cited by 19)
  26. Qin X, Hu W, Song W, Blair P, Wu G, Hu X, Song Y, Bauer S, Feelisch M, Leopold JA, Loscalzo J, Halperin JA. The balancing role of nitric oxide in complement-mediated platelet activation of mCd59a and mCd59b double-knockout mice. American Journal of Hematology. 2009;84(4):221-227. (IF:4.671) (cited by 21)
  27. Qin X, Hu W, Song W, Grubissich L, Hu X, Wu G, Ferris S, Dobarro M, and Halperin JA. Generation and phenotyping of a mCd59a and mCd59b double-knockout mice. American Journal of Hematology. 2008;84:65-70. (IF:4.671) (cited by 20)
  28. Zhou X, Hu W, and Qin X. The Role of Complement in the Mechanism of Action of Rituximab for B-Cell Lymphoma: Implications for Therapy. The Oncologist. 2008;13(9):854-966. (IF:6.701) (cited by 84)
  29. Hu W, Ferris S, Tweten RK, Wu G, Bronson RT, Halperin JA and Qin X. Conditional, rapid and targeted ablation of cells expressing human CD59 in transgenic mice by intermedilysin. Nature Medicine. 2008;14:98-103. (IF:27.136) (cited by 25)
  30. Qin X, Gao B. The complement system in liver diseases. Cell Mol Immunol. 2006;3(6):333-340. (IF:2.992) (cited by 83)
  31. Qin X, Ferris X, Hu W, Feng G, Ziegeler G, and Halperin JA. Analysis of the Promoters and 5’-UTR of Mouse Cd59 Genes, and of their Functional Activity in Erythrocytes. Genes and Immunity. 2006;7(4):287-297. (IF:3.872) (cited by 13)
  32. Qin X, Dobarro M, Bedford SJ, Ferris S, Miranda PV, Bronson RT, Visconti PE, & Halperin JA. Further characterization of the reproductive abnormalities in mCd59b knockout mice: A potential new function of mCd59 in male reproduction. Journal of Immunolgy. 2005;175(10):6294-9302. (IF:5.788) (cited by 18)
  33. Qin X, Goldfine A, Krumrei N,Grubissich L, Acosta J, Chorev M, Hays AP, Halperin JA. Glycation-inactivation of the complement regulatory protein CD59: A possible role in the pathogenesis of the vascular complications of human disease. Diabetes. 2004;53:2653-2661. (IF:8.3) (cited by 85)
  34. Acosta J, Qin X, Halperin JA. Complement and complement regulatory proteins as potential molecular targets for vascular diseases. Current Pharmaceutical Design. 2004;10:203-211. (IF:3.87) (cited by 69)
  35. Qin X, Krumrei N, Grubissich L, Dobarro M, Aktas H, Perez G, Halperin JA. Deficiency of the mouse complement regulatory protein mCd59b results in spontaneous hemolytic anemia with platelet activation and progressive male infertility. Immunity. 2003;18:217-227 (IF:21.091) (cited by 57)
  36. Gao H, Boustany RM, Espinola JA, Cotman SL, Srinidhi L, Antonellis KA, Gillis T, Qin X, Liu S, Donahue LR, Bronson RT, Faust JR, Stout D, Haines JL, Lerner TJ, MacDonald ME. Mutations in a novel CLN6-encoded transmembrane protein cause variant neuronal ceroid lipofuscinosis in man and mouse. American Journal of Human Genetics. 2002;70:324-335. (IF:10.603) (cited by 167)
  37. Qin X, Miwa T, Aktas H, Gao M, Lee C, Qian Y-M, Morton C, Shahsafaei A, Song W, Halperin JA. Genomic structure, functional comparison, and tissue distribution of mouse Cd59a and Cd59b. Mammalian Genome. 2001;12:582-589 (IF:2.887) (cited by 47)
  38. Qian Y, Qin X, (Co-first author), Miwa T, Sun X, Halperin JA, Song W. Identification and functional characterization of a new gene encoding the mouse terminal complement inhibitor CD59. J Immunol. 2000;165:2528-2534. (IF:5.788) (cited by 62)
  39. Huang T, Lan-Ying L, Shen Y, Qin X, Wu G. Alternative splicing expression of FMR-1 gene in human fetal neuron. Am J Med Genet. 1996;64(2):252-255. (IF:2.391) (cited by 15)